Andrew Boll Biography and Net Worth

President & Chief Financial Officer of Harrow

Andrew R. Boll, a founding employee of Harrow, serves as President, Chief Financial Officer and Corporate Secretary, overseeing the Company’s financial, market access and administrative operations. Mr. Boll also co‑founded Eton Pharmaceuticals (Nasdaq: ETON), Melt Pharmaceuticals, Surface Ophthalmics, and ImprimisRx. Before joining Harrow, he managed accounting, financial analysis, and reporting for an investment company from 2007 to 2011, and he was also heavily involved with the financial operations of a number of the fund’s portfolio companies (public and private). Prior to 2007, Mr. Boll held various accounting roles at Welsh Companies, a commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA® charterholder, a Certified Management Accountant (CMA®), and graduatedsumma cum laude with a Bachelor of Science in Corporate and Public Finance.

What is Andrew R. Boll's net worth?: The estimated net worth of Andrew R. Boll is at least $28.29 million as of May 14th, 2026. Mr. Boll owns 814,679 shares of Harrow stock worth more than $28,285,655 as of June 5th. This net worth estimate does not reflect any other assets that Mr. Boll may own. Learn More about Andrew R. Boll's net worth.
How do I contact Andrew R. Boll?: The corporate mailing address for Mr. Boll and other Harrow executives is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. Harrow can also be reached via phone at (615) 733-4730 and via email at [email protected]. Learn More on Andrew R. Boll's contact information.
Has Andrew R. Boll been buying or selling shares of Harrow?: Within the last three months, Andrew R. Boll has bought $104,650.00 of Harrow stock. Most recently, on Thursday, May 14th, Andrew R. Boll bought 3,500 shares of Harrow stock. The stock was acquired at an average cost of $29.90 per share, with a total value of $104,650.00. Following the completion of the transaction, the chief financial officer now directly owns 814,679 shares of the company's stock, valued at $24,358,902.10. Learn More on Andrew R. Boll's trading history.
Who are Harrow's active insiders?: Harrow's insider roster includes Mark Baum (Chief Executive Officer and Chairman of the Board of Directors), Andrew Boll (President & Chief Financial Officer), and Richard Lindstrom, MD (Director). Learn More on Harrow's active insiders.
Are insiders buying or selling shares of Harrow?: In the last twelve months, Harrow insiders bought shares 2 times. They purchased a total of 4,500 shares worth more than $135,720.00. The most recent insider tranaction occured on May, 18th when Director Adrienne L Graves bought 1,000 shares worth more than $31,070.00. Insiders at Harrow own 12.8% of the company. Learn More about insider trades at Harrow.
Information on this page was last updated on 5/18/2026.

Andrew R. Boll Insider Trading History at Harrow

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2026	Buy	3,500	$29.90	$104,650.00	814,679
12/22/2022	Buy	2,500	$13.54	$33,850.00	255,063
12/19/2016	Buy	39,000	$1.79	$69,810.00	54,000

Andrew R. Boll Buying and Selling Activity at Harrow

Harrow Company Overview

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $34.36

$34.01

$34.90

50 Day Range

MA: $35.99

$29.03

$41.50

2 Week Range

Now: $34.36

$28.54

$54.85

Volume

130,734 shs

Average Volume

745,867 shs

Market Capitalization

$1.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28